Delforge, Michel

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 2,560

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 900

Neutrophil extracellular trap cell death requires both autophagy and superoxide generation

Remijsen, Q., Berghe, T. V., Wirawan, E., Asselbergh, B., Parthoens, E., De Rycke, R., Noppen, S., Delforge, M., Willems, J., & Vandenabeele, P. (2011) · Cell Research

Neutrophil, Myeloperoxidase and Oxidative MechanismsCell death mechanisms and regulation

Cited by 818

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., et al. (2023) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsCAR-T cell therapy research

Cited by 781

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 721

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., et al. (2024) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 599

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Kumar, S. K., Dimopoulos, M. A., Kastritis, E., Terpos, E., Nahi, H., Goldschmidt, H., Hillengass, J., Leleu, X., Beksac, M., Alsina, M., et al. (2017) · Leukemia

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 351

Multiple myeloma: patient outcomes in real‐world practice

Yong, K., Delforge, M., Driessen, C., Fink, L., Flinois, A., Gonzalez‐McQuire, S., Safaei, R., Karlin, L., Mateos, M., Raab, M. S., et al. (2016) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 326

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Facon, T., Dimopoulos, M. A., Dispenzieri, A., Catalano, J. V., Belch, A., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N. J., et al. (2018) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 271

Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma

Palumbo, A., Gay, F., Cavallo, F., Di Raimondo, F., Larocca, A., Hardan, I., Nagler, A., Petrucci, M. T., Hajek, R., Pezzatti, S., et al. (2015) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 150

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.

Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., Bahlis, N. J., et al. (2024) · Blood

Multiple Myeloma Research and TreatmentsCAR-T cell therapy research

Cited by 79

Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).

van de Donk, N. W. C. J., Moreau, P., Garfall, A. L., Bhutani, M., Oriol, A., Nooka, A. K., Martin, T. G., Rosiñol, L., Mateos, M.-V., Bahlis, N. J., et al. (2023) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 71

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., et al. (2022) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 48

Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

Delforge, M., Patel, K., Eliason, L., Dhanda, D., Shi, L., Guo, S., Marshall, T. S., Arnulf, B., Cavo, M., Nooka, A., et al. (2024) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsCAR-T cell therapy research

Cited by 31

Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1–3 prior lines of therapy (LOT): CARTITUDE-2, cohort A.

Einsele, H., Cohen, A. D., Delforge, M., Hillengass, J., Goldschmidt, H., Weisel, K., Raab, M.-S., Scheid, C., Schecter, J. M., De Braganca, K. C., et al. (2022) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 7

Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).

Moreau, P., Usmani, S. Z., van de Donk, N. W. C. J., Garfall, A. L., Delforge, M., Oriol Rocafiguera, A., Nooka, A. K., Rosiñol, L., Bahlis, N. J., Rodríguez-Otero, P., et al. (2022) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsStatistical Methods in Clinical Trials

Cited by 5